OncoMatch/Clinical Trials/NCT06545942
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Is NCT06545942 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including MOMA-313 and Olaparib for advanced solid tumor.
Treatment: MOMA-313 · Olaparib — This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Prostate Cancer
Pancreatic Cancer
Breast Carcinoma
Ovarian Cancer
Disease stage
Metastatic disease required
Advanced (including locally), relapsed or metastatic solid tumors that are not eligible for curative therapy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: polymerase theta inhibitor
Prior polymerase theta inhibitor exposure
Lab requirements
Blood counts
adequate organ function per local labs
Kidney function
adequate organ function per local labs
Liver function
adequate organ function per local labs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Investigative Site #108 · Goodyear, Arizona
- Investigative Site #101 · La Jolla, California
- Investigative Site #111 · San Francisco, California
- Investigative Site #104 · Lake Mary, Florida
- Investigative Site #110 · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify